Defining path-to-market strategy through a data-driven and scientific approach
Certara was approached by a private gene therapy company specializing in the development of RNA carriers. Their therapeutic areas of interest are antivirals, cancer immunotherapies, and gene & cell therapies. The client had licensed a highly safe and easy-to-use lentiviral vector technology that can efficiently deliver RNAs in vitro and in vivo. However, the company had not yet identified therapeutic indications to target.
By considering a commercial lens through which to view a choice of indications to pursue, Certara helped our client de-risk the development at this early stage where commercial considerations are usually absent.